CurifyLabs Raises $14M for 3D-Printed Meds

Jan de Vries · 2026-07-06

### The Big News: CurifyLabs' $14 Million Series A CurifyLabs, a HealthTech company based in Helsinki, just announced they've closed a $14 million Series A funding round. They're using that money to expand their U.S. operations, strengthen their supply chain, improve customer support, and speed up product development. The round was co-led by Sandwater and HealthCap, with participation from Tesi and existing investors like Lifeline Ventures. This comes after they raised $7.3 million back in May 2025. "This investment reflects the conviction our partners have in what we're building," says Charlotta Topelius, CEO and founder of CurifyLabs. "We have set a high bar for clinical rigor, product quality, and customer support, and this funding gives us the resources to raise that bar further." ### What's Driving the Investment? Personalized medicine is one of the hottest areas in healthcare right now. It's all about tailoring treatments to individual patients, which leads to better outcomes. CurifyLabs is right in the middle of this trend, helping pharmacies deliver personalized medicine more safely and efficiently. Morten E. Iversen, partner at Sandwater, puts it this way: "Personalized medicine is one of the most important frontiers in healthcare enabling better patient outcomes and is experiencing solid growth. We are enabling more pharmacies to deliver personalized medicine in a safer and more efficient way." He adds, "CurifyLabs has built something rare - technology that combines clinical rigor with the speed and precision that busy pharmacy teams depend on. We are excited to support their rapid growth in the U.S. and beyond." ### How CurifyLabs' Technology Works Founded in 2021, CurifyLabs created the Compounding System Solution (CSS). It's a system that combines proprietary software, GMP-manufactured excipient bases, and advanced 3D printing technology. Together, these automate the preparation of personalized medications. Think of it like this: instead of a pharmacist manually mixing ingredients for each prescription, the system does it automatically with precision. That means fewer errors, faster turnaround, and better consistency. Right now, pharmacies in 21 U.S. states and across Europe use CurifyLabs technology to compound and dispense thousands of doses every single day. ### The Funding Landscape in 2026 CurifyLabs' Series A is part of a bigger wave of investments in personalized health, diagnostics, and healthcare infrastructure. Here are some other notable rounds from 2026: - **Rem3dy Health:** Raised $17.4 million for personalized health expansion - **ShanX Medtech:** Secured $26.1 million for antimicrobial-susceptibility diagnostics - **Xyall:** Closed $8.3 million for automated molecular pathology workflows - **SamanTree Medical:** Got $21.7 million from the EIB for surgical imaging - **ScreenPoint Medical:** Raised $14.8 million for AI-powered breast cancer detection - **BioLamina:** Received $21.7 million EIB loan for cell-therapy infrastructure - **Helical:** Raised $9.1 million Seed round for pharma R&D software - **Astral Systems:** Closed $28.3 million Series A for medical-isotope supply infrastructure All together, these adjacent announcements add up to about $149 million in disclosed funding. That's a lot of money flowing into the space, and it shows how much investors believe in personalized medicine. ### What This Means for CurifyLabs' Growth Daniel Karsberg, partner at HealthCap, explains why they invested: "We have backed more than 136 life sciences companies over nearly three decades, and what sets the best founders apart is their ability to combine scientific depth with real-world execution. The CurifyLabs team has done exactly that." The funding will support ongoing development of the CurifyLabs platform, including their latest product, the PharmaPrinter Aurum. This machine reportedly compounds medications up to nine times faster than manual processes. That's a huge leap in efficiency for busy pharmacies. ### Compliance and Certification CurifyLabs' technology is ISO 13485 certified, which means it meets international standards for medical devices. It's also designed to comply with FDA 503A and 503B standards for non-sterile compounding. That's important because it means pharmacies can use the system with confidence, knowing it meets regulatory requirements. Joni Karsikas, Investment Director at Tesi, sums it up: "CurifyLabs is the kind of company we want to support - innovative, globally ambitious, and built on deep scientific expertise. Their growth in the U.S. is further proof that Finnish health technology can compete and win on the world stage." ### The Bottom Line CurifyLabs is making personalized medicine more accessible and reliable. With this new funding, they're poised to scale their operations in the U.S. and beyond. For pharmacies looking to improve efficiency and patient outcomes, their technology offers a compelling solution.